Thymalin is a synthetic peptide related to thymulin, a thymus-derived factor originally described in the late 1970s. In laboratory research, thymulin-related peptides are used as molecular tools to investigate thymus-associated immunoregulatory signaling, including pathways linked to T-lymphocyte differentiation, lymphoid organ physiology, and cytokine-regulated immune responses in controlled experimental systems.

Research interest in thymulin-related peptides also extends to neuroimmune signaling frameworks where endocrine and circadian variables are evaluated as modulators of immune-cell phenotypes in preclinical models.

Source: PubChem

Sequence: Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn
Molecular Formula: C₃₃H₅₄N₁₂O₁₅
Molecular Weight: 858.864 g/mol
PubChem CID: 3085284
CAS Number: 63958-90-7
Synonyms: Thymulin, Thymic Factor, Nonathymuli, Facteur Thymique Serique, Serum Thymic Factor

In mechanistic literature, thymulin activity is commonly discussed in relation to metal-ion dependence (notably zinc) and peptide–protein interactions that influence immunophenotyping readouts in cell-based assays. The nonapeptide format supports controlled evaluation of sequence-dependent activity in vitro and in vivo animal systems.

Thymalin is supplied exclusively for laboratory research and may be utilized in studies including (non-exhaustive):

• T-cell lineage and thymocyte differentiation assays (cellular immunology workflows)
• Natural killer (NK) cell and lymphocyte subpopulation profiling in experimental models
• Cytokine/chemokine signaling modulation studies in immune-cell culture systems
• Neuroimmune and circadian-associated immune fluctuation models in animals
• Exploratory tumor–immune interaction studies in vivo (immune organ readouts under controlled conditions)

Thymulin-related peptides are studied as immunoregulatory signals associated with thymus function and peripheral immune homeostasis. In experimental systems, mechanistic endpoints commonly evaluated include shifts in lymphocyte maturation markers, changes in immune effector-cell activity signatures, and modulation of inflammatory signaling mediators measured via standard laboratory assays (e.g., flow cytometry panels, cytokine quantification, and transcript/protein expression readouts).

A recurring mechanistic theme in the literature is zinc-dependent activity, where metal-ion availability is examined as a variable influencing thymic-factor functionality and immune response phenotypes in controlled models.

1. Biochemical Characterization and Thymic-Factor Activity Models

Foundational work describing serum thymic factor/thymulin includes biochemical characterization and activity modeling that established a framework for subsequent immune-cell readouts and assay development^[4].

2. Experimental Immune Modulation in Animal Models

Animal studies have evaluated thymulin-related peptides in models assessing thymocyte proliferation/apoptosis dynamics and endocrine–immune interactions (e.g., post-surgical endocrine manipulation paradigms), supporting investigation of thymus-linked regulation under controlled conditions^[9].

3. Circadian-Associated Immune Fluctuation Frameworks

Preclinical literature has examined age- and rhythm-associated immune fluctuations and the relationship of thymic factors to immune phenotype variability in animal models, providing experimental context for neuroimmune and endocrine coupling investigations^[21].

4. Lipid/Inflammation-Linked Experimental Models

Rabbit research has explored thymic-factor peptides in experimental hyperlipidemia/atherosclerosis settings with laboratory endpoints that include lipid measures and immune readouts within that model framework^[22].

5. Tumor–Immune Contexts in Vivo

In vivo studies have examined thymic peptides in tumor-bearing animal models, reporting tumor- and thymus-associated endpoints under defined experimental conditions, supporting continued mechanistic interrogation of immune-organ responses in oncology research contexts^[13].

6. Zinc-Dependent Thymulin Activity

Because thymulin activity is discussed as zinc-dependent in mechanistic literature, experimental work has evaluated how nutritional/trace-element variables relate to thymic-factor activity readouts, informing assay design and interpretation where metal-ion availability is a controlled variable^[25].

Thymalin is supplied as a synthetic peptide intended for laboratory handling. Identity and purity are verified using standard analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Batch-specific analytical documentation supports reproducibility and experimental consistency.

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Vladimir Khavinson is cited in the referenced literature as a researcher associated with peptide bioregulator studies in aging and immune regulation. Referencing an author does not imply endorsement of any product or use.

Prof. Vladimir Khavinson is listed in [1], [2], [20] and [24] under the referenced citations.

1. J. Bach, M. Bardenne, J. Pleau, and J. Rosa, “Biochemical characterisation of a serum thymic factor,” Nature, vol. 266, no. 5597, pp. 55–57, Mar. 1977.
2. I. I. Hrinevych, H. D. Bendiuh, N. M. Khranovs’ka, I. M. Bilokin’, and O. M. Ostapenko, “[Effect of thyroxin and thymalin on proliferation and apoptosis of thymocytes in rats after thyroidectomy],” Fiziolohichnyi Zhurnal, vol. 50, no. 3, pp. 39–43, 2004.
3. G. V. Zhukova, A. I. Schikhlyarova, T. A. Barteneva, A. N. Shevchenko, and F. M. Zakharyuta, “Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo,” Bull. Exp. Biol. Med., vol. 165, no. 1, pp. 80–83, May 2018.
4. I. F. Labunets’, “[Age-related changes in circadian and circannual fluctuations of the immune response and the number of cells in lymphoid organs of animals: a possible connection to thymic factors],” Fiziolohichnyi Zhurnal, vol. 47, no. 5, pp. 54–62, 2001.
5. V. E. Ryzhenkov, R. P. Ogurtsov, V. V. Trubacheva, V. G. Popov, and V. P. Puzyreva, “[Effect of thymalin on the development of experimental hyperlipidemia and atherosclerosis],” Vopr. Med. Khim., vol. 34, no. 1, pp. 51–56, Feb. 1988.
6. S. Wade et al., “Thymulin (Zn-facteur thymique serique) activity in anorexia nervosa patients,” Am. J. Clin. Nutr., vol. 42, no. 2, pp. 275–280, Aug. 1985.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.